- Home
- EDN vs NVAX Comparison
EDN vs NVAX Comparison
Compare EDN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDN | NVAX |
|---|---|---|
| Founded | 1992 | 1987 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2007 | 1996 |
Fundamental Metrics
Financial Performance| Metric | EDN | NVAX |
|---|---|---|
| Price | $23.63 | $9.96 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 63.8K | ★ 5.3M |
| Earning Date | 03-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $13.19 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $14.38 | $6.20 |
| 52 Week High | $36.70 | $11.85 |
Technical Indicators
Market Signals| Indicator | EDN | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 60.72 |
| Support Level | $22.09 | $9.12 |
| Resistance Level | $29.64 | $10.36 |
| Average True Range (ATR) | 1.03 | 0.62 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 40.05 | 54.53 |
Price Performance
Historical ComparisonAbout EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires, mainly for residential, commercial, industrial, and public service.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.